- Home
- NRXS vs BRTX Comparison
NRXS vs BRTX Comparison
Compare NRXS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- BRTX
- Stock Information
- Founded
- NRXS 2011
- BRTX 1997
- Country
- NRXS United States
- BRTX United States
- Employees
- NRXS N/A
- BRTX N/A
- Industry
- NRXS
- BRTX Managed Health Care
- Sector
- NRXS
- BRTX Health Care
- Exchange
- NRXS Nasdaq
- BRTX Nasdaq
- Market Cap
- NRXS 13.0M
- BRTX 12.5M
- IPO Year
- NRXS 2023
- BRTX N/A
- Fundamental
- Price
- NRXS $2.77
- BRTX $1.62
- Analyst Decision
- NRXS Strong Buy
- BRTX Strong Buy
- Analyst Count
- NRXS 1
- BRTX 1
- Target Price
- NRXS $7.00
- BRTX $18.00
- AVG Volume (30 Days)
- NRXS 85.1K
- BRTX 89.6K
- Earning Date
- NRXS 08-08-2025
- BRTX 08-12-2025
- Dividend Yield
- NRXS N/A
- BRTX N/A
- EPS Growth
- NRXS N/A
- BRTX N/A
- EPS
- NRXS N/A
- BRTX N/A
- Revenue
- NRXS $2,934,945.00
- BRTX $391,000.00
- Revenue This Year
- NRXS $138,883.78
- BRTX $216.71
- Revenue Next Year
- NRXS $118.59
- BRTX $60.63
- P/E Ratio
- NRXS N/A
- BRTX N/A
- Revenue Growth
- NRXS 27.52
- BRTX 161.54
- 52 Week Low
- NRXS $1.33
- BRTX $1.21
- 52 Week High
- NRXS $6.20
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- NRXS 57.38
- BRTX 48.45
- Support Level
- NRXS $2.55
- BRTX $1.43
- Resistance Level
- NRXS $2.92
- BRTX $1.75
- Average True Range (ATR)
- NRXS 0.17
- BRTX 0.12
- MACD
- NRXS 0.03
- BRTX 0.01
- Stochastic Oscillator
- NRXS 78.26
- BRTX 52.78
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.